Frazier Life Sciences Management L.P. bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 69,406 shares of the biopharmaceutical company’s stock, valued at approximately $16,059,000. Frazier Life Sciences […]
Paulson & CO. Inc. increased its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 121.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,105,741 shares of the biopharmaceutical company’s stock after purchasing an additional 605,741 shares during the quarter. Madrigal […]
Bain Capital Life Sciences Investors LLC bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 324,619 shares of the biopharmaceutical company’s stock, valued at approximately $75,110,000. Madrigal Pharmaceuticals comprises approximately […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Wednesday. Other equities research analysts also recently issued research reports about the company. Piper Sandler restated an “overweight” rating and set a $336.00 price target on shares […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Wednesday. Other equities research analysts also recently issued research reports about the company. Piper Sandler restated an “overweight” rating and set a $336.00 price target on shares […]